Phytopharm plc (Phytopharm) is a development-stage pharmaceutical company. The Company�s lead programs target neurodegenerative diseases, including Parkinson�s disease, amyotrophic lateral sclerosis and glaucoma. As of September 30, 2011, Phytopharm was focused on the treatment advances in its target areas of neurodegeneration and inflammatory disease. Its lead series of compounds are the Sapogenins (including Cogane and Myogane). The Company�s products, Cogane and Myogane, are structurally related, small-molecule, chemical entities and members of the Sapogenin class of compounds. They are orally bioavailable neurotrophic factor modulators that readily cross the blood-brain barrier. Both compounds have demonstrated neuroprotective effects in a range of preclinical models.